WCPT 820 Interview: Joe Cunningham of Pharmaceutical Reform Alliance

Chew's Views with Richard Chew (Featured Interviews)

From Heartland Signal and WCPT AM 820 in Chicago, here is a collection of the most interesting and important interviews that air on “Chew's Views” (we…

743 clip(s)

Loading playlist

Richard Chew is joined by Joe Cunningham, former congressman who now serves as spokesperson for the Pharmaceutical Reform Alliance; he discusses PRA’s new report on big pharma and drug prices. They discuss political leadership, economic affordability, and the necessity of pharmaceutical reform.

Joe Cunningham's Background
- Joe Cunningham is a Democratic politician from Charleston, South Carolina, who previously served in a district (South Carolina's 1st Congressional District) that had not elected a Democrat in almost 40 years.
- He was part of the 2018 freshman class of leadership and later ran as the Democratic nominee for governor of South Carolina in 2022.

Political Momentum and Challenges
- Cunningham argues that current economic hardships and failed policies have created a growing frustration among Americans.
- He highlights the disparity between government spending on things like D.C. infrastructure and the struggles citizens face with rent and groceries.
- The discussion touches on the need for new generational leadership to address these systemic issues.

Affordability and Accountability
- Chew and Cunningham discuss how affordability and accountability are deeply interconnected in the minds of voters.
- Cunningham notes that frustration grows when people see government officials profiting from stock trades or misusing funds while citizens struggle.

Democratic Party Opportunities
- Cunningham suggests the Democratic Party needs to rebuild credibility by speaking directly to voters rather than talking down to them.
- He advocates for moving beyond just criticizing opponents and instead presenting bold, New Deal-style ideas to uplift Americans.
- The conversation emphasizes the importance of being results-driven rather than focusing solely on political accountability.

Prescription Drug Pricing Reform
- Cunningham explains that Americans pay roughly three times more for prescription drugs than people in other developed nations.
- He promotes the "most favored nation" policy, which aims to bring U.S. drug prices in line with global averages.
- This specific policy reportedly enjoys high bipartisan support, including interest from both Democrats and some Republicans like Marjorie Taylor Greene.

Big Pharma Lobbying Influence
- The discussion highlights how the pharmaceutical industry uses massive amounts of money to lobby Congress and block price reform.
- Cunningham points out that some conservative groups receive significant funding from pharmaceutical trade associations to oppose drug pricing legislation.
- High costs lead to a compounding strain on the health care system as patients skip doses or delay necessary care due to expense.

Future Outlook for Healthcare Reform
- Cunningham notes that while accountability is important, the party must also deliver tangible results like lower health care costs.
- He mentions the rising popularity of GLP medications but emphasizes that their benefits are limited by high price tags in the U.S. compared to Japan or The Netherlands.
- The segment concludes with an emphasis on using potential legislative wins in future elections to drive meaningful pharmaceutical reform.